Sex hormones and colorectal cancer: What have we learned so far?

Journal of the National Cancer Institute

Volumn 102, Issue 23, 2010, Pages 1746-1747

  Lin, Jennifer H ^a   Giovannucci, Edward ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; AZOXYMETHANE; BETA CATENIN; CYCLIN D1; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; PLACEBO; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; VITAMIN D;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CARCINOGENESIS; CASTRATION; COLONOSCOPY; COLORECTAL CANCER; EDITORIAL; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; OBESITY; ORCHIECTOMY; PHYSICAL ACTIVITY; PREGNANCY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SIGMOIDOSCOPY; TRANSCRIPTION INITIATION; TREATMENT DURATION; TUMOR REGRESSION;

ANDROGEN ANTAGONISTS; ANTICARCINOGENIC AGENTS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; GONADOTROPIN-RELEASING HORMONE; HUMANS; LIFE STYLE; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROGESTERONE; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 78649900291     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq444     Document Type: Editorial

References (22)

1. La Vecchia C, Franceschi S. Reproductive factors and colorectal cancer. Cancer Causes Control. 1991;2(3):193-200.
2. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer. 2001;84(5):722-727. (Pubitemid 32239011)
3. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106(5):574-582. (Pubitemid 29231110)
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefts of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
5. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991-1004.
6. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
7. Ritenbaugh C, Stanford JL, Wu L, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008;17(10): 2609-2618.
8. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008;68(1):329-337. (Pubitemid 351380136)
9. Clendenen TV, Koenig KL, Shore RE, Levitz M, Arslan AA, Zeleniuch-Jacquotte A. Postmenopausal levels of endogenous sex hormones and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(1):275-281.
10. Slattery ML, Sweeney C, Murtaugh M, et al. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2936-2942. (Pubitemid 43068828)
11. Alberg AJ, Gordon GB, Hoffman SC, Comstock GW, Helzlsouer KJ. Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and the subsequent risk of developing colon cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(5):517-521.
12. Gillessen S, Templeton A, Marra G, Kuo Y-F, Valtorta E, Shahinian VB. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 2010;102(23):1760-1770.
13. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology.138(6):2029-2043. e10.
14. Izbicki JR, Hamilton SR, Wambach G, et al. Effects of androgen manipulations on chemically induced colonic tumours and on macroscopically normal colonic mucosa in male Sprague-Dawley rats. Br J Cancer. 1990;61(2):235-240.
15. Pereira MA, Khoury MD. Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon. Cancer Lett. 1991;61(1):27-33.
16. Stebbings WS, Vinson GP, Farthing MJ, Balkwill F, Wood RF. Effect of steroid hormones on human colorectal adenocarcinoma xenografts, of known steroid-receptor status, in nude mice. J Cancer Res Clin Oncol. 1989;115(5):439-444.
17. Chesire DR, Isaacs WB. Ligand-dependent inhibition of beta-catenin/ TCF signaling by androgen receptor. Oncogene. 2002;21(55):8453-8469.
18. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007;132(6):2208-2225.
19. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005;63(3):239-250.
20. Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med. 1992;1(6):329-336.
21. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007;86(3):556-565. (Pubitemid 47435820)
22. Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22(14):2927-2941.